CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia

Clinical responses to bendamustine in chronic lymphocytic leukemia (CLL) are highly heterogeneous and no specific markers to predict sensitivity to this drug have been reported. In order to identify biomarkers of response, we analyzed the in vitro activity of bendamustine and the gene expression pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Montraveta, Arnau, Lee-Vergés, Eriong, Roldán, Jocabed, Jiménez, Laura, Cabezas, Sandra, Clot, Guillem, Pinyol, Magda, Xargay-Torrent, Sílvia, Rosich, Laia, Arimany-Nardí, Cristina, Aymerich, Marta, Villamor, Neus, López-Guillermo, Armando, Pérez-Galán, Patricia, Roué, Gaël, Pastor-Anglada, Marçal, Campo, Elías, López-Guerra, Mónica, Colomer, Dolors
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868702/
https://www.ncbi.nlm.nih.gov/pubmed/26701728
http://dx.doi.org/10.18632/oncotarget.6685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868702/
https://www.ncbi.nlm.nih.gov/pubmed/26701728
http://dx.doi.org/10.18632/oncotarget.6685

Ejemplares similares